| Primary information |
|---|
| sequence ID | Seq_7091 |
| Peptide sequence | SGEGDFLAEGGGV |
| CancerPDF_ID | CancerPDF_ID640, CancerPDF_ID1215, CancerPDF_ID8509, CancerPDF_ID9661, CancerPDF_ID12182, |
| PMID | 19795908,21136997,23667664,21533267,26992070 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Plasma,Serum,Serum,Serum,Serum |
| M/Z | 597.76,1193.52005,1193.52,597.75,1193.52 |
| Charge | 2,1,1,2,NA |
| Mass (in Da) | NA,NA,1195.23,NA,1194.52788 |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,MALDI-TOF,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,NA,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,0.001,NA,1.49,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID640, CancerPDF_ID1215, CancerPDF_ID8509, CancerPDF_ID9661, CancerPDF_ID12182, |
| p-Value | NA,3.75E-04,NA,4.44E-24,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT,MASCOT,SEQUEST and Maxquant |
| Length | 13,13,13,13,13 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Melanoma |
| Database | NCBI refseq Protein Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,NA,NA |
| Number of Patients | "42 normal, 28patients",30 patients and 30 healthy controls,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
| Regulation | NA,Differentially expressed between cancer vs normal,NA,Differentially expressed between Lung cancer vs control,"Present in 8 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." |
| Validation | NA,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,na |
| Sensitivity | NA,0.898,NA,NA,NA |
| Specificity | NA,0.946,NA,NA,NA |
| Accuracy | NA,0.917,NA,0.769,NA |
| Peptide Atlas | NA |
| IEDB | 462581
|